These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34627611)

  • 1. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K
    Gynecol Oncol; 2021 Dec; 163(3):473-480. PubMed ID: 34627611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
    Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
    Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
    Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
    Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
    J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Hamilton E; O'Malley DM; O'Cearbhaill R; Cristea M; Fleming GF; Tariq B; Fong A; French D; Rossi M; Brickman D; Moore K
    Gynecol Oncol; 2020 Sep; 158(3):640-645. PubMed ID: 32513564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
    Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
    Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
    Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
    Smaletz O; Diz MD; do Carmo CC; Sabbaga J; Cunha-Junior GF; Azevedo SJ; Maluf FC; Barrios CH; Costa RL; Fontana AG; Madrigal V; Wainstein AJ; Yeda FP; Alves VA; Moro AM; Blasbalg R; Scott AM; Hoffman EW
    Gynecol Oncol; 2015 Aug; 138(2):272-7. PubMed ID: 26026738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
    Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
    Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
    Fowler M
    Oncology (Williston Park); 2020 Jul; 34(7):250. PubMed ID: 32674207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.